News Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq Other stock markets 04:00:04 2024-04-23 pm EDT			5-day change	1st Jan Change
4.555 ^USD	-4.71%		-15.33%	+21.79%

Apr. 22	Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	CI
Mar. 21	Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	Apr. 22	GL
Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	Apr. 22	CI
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	Apr. 03	AQ
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	GL
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	Apr. 02	GL
Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	Mar. 20	CI
Fate Therapeutics Prices $100 Million Offering, Private Placement	Mar. 19	MT
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement	Mar. 19	GL
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC	Mar. 18	CI
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Transcript : Fate Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM	Mar. 12
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	Mar. 06	AQ
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	Mar. 05	GL
Fate Therapeutics to Present at Upcoming March Investor Conferences	Mar. 04	AQ
Fate Therapeutics to Present at Upcoming March Investor Conferences	Mar. 01	GL
Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating	Feb. 27	MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating	Feb. 27	MT
Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating	Feb. 27	MT
Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating	Feb. 27	MT
Transcript : Fate Therapeutics, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Summary

Filters